Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles | Zendy

Ziaurrehman Tanoli | Zendy; Zaid Alam | Zendy; Markus VähäKoskela | Zendy; Balaguru Ravikumar | Zendy; Alina Malyutina | Zendy; Alok Jaiswal | Zendy; Jing Tang | Zendy; Krister Wennerberg | Zendy; Tero Aittokallio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug Target Commons 2.0: a community platform for systematic analysis of drug–target interaction profiles

Author(s) -

Ziaurrehman Tanoli,

Zaid Alam,

Markus VähäKoskela,

Balaguru Ravikumar,

Alina Malyutina,

Alok Jaiswal,

Jing Tang,

Krister Wennerberg,

Tero Aittokallio

Publication year - 2018

Publication title -

database

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.406

H-Index - 62

ISSN - 1758-0463

DOI - 10.1093/database/bay083

Subject(s) - upload , drug repositioning , computer science , standardization , interface (matter) , reuse , world wide web , repurposing , download , workflow , drug development , commons , data integration , drug , database , medicine , engineering , biology , pharmacology , operating system , bubble , maximum bubble pressure method , waste management , ecology

Drug Target Commons (DTC) is a web platform (database with user interface) for community-driven bioactivity data integration and standardization for comprehensive mapping, reuse and analysis of compound-target interaction profiles. End users can search, upload, edit, annotate and export expert-curated bioactivity data for further analysis, using an application programmable interface, database dump or tab-delimited text download options. To guide chemical biology and drug-repurposing applications, DTC version 2.0 includes updated clinical development information for the compounds and target gene-disease associations, as well as cancer-type indications for mutant protein targets, which are critical for precision oncology developments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research